Open AccessIn vitro evaluation of a new injectable calcium phosphate material
Author(s) -
Grimandi G.,
Weiss P.,
Millot F.,
Daculsi G.
Publication year - 1998
Publication title -
journal of biomedical materials research
Language(s) - English
Resource type - Journals
eISSN - 1097-4636
pISSN - 0021-9304
DOI - 10.1002/(sici)1097-4636(19980315)39:4<660::aid-jbm22>3.0.co;2-9
Subject(s) - biomaterial , biocompatibility , materials science , biomedical engineering , polymer , calcium , solubility , in vivo , composite material , chemistry , nanotechnology , medicine , metallurgy , biology , microbiology and biotechnology , organic chemistry
The purpose of this study was to develop an injectable bone substitute (IBS) for percutaneous orthopedic surgery. The multiphasic material used was composed of a 2% aqueous solution of methylhydroxypropylcellulose (MHPC) and biphasic calcium phosphate (BCP, 60% hydroxyapatite and 40% β‐tricalcium phosphate) in which MHPC served as the carrier for 80–200 μm of BCP granules. The best BCP/polymer ratio was determined by the rheological properties and higher BCP content of the material. Steam sterilization was more effective than gamma irradiation in maintaining the stability of the mixture and conserving its physiochemical and mechanical properties. The in vitro biocompatibility of the composite was checked by direct‐contact cytotoxicity and cell‐proliferation assays. A preliminary in vivo test was performed in the rabbit using intraosseous implantations in the femoral epiphysis. Histological analysis was done after 1, 2, 4, and 10 weeks. Bone ingrowth into the IBS, in close association with BCP granules, was observed after 1 week and increased regularly from the surface inward at 2, 4, and 10 weeks. At the same time, smaller BCP granules (less than 80 microns in diameter) were degraded and resorbed. This injectable biomaterial proved suitable for cavity filling. The water solubility and viscosity of the polymer allow cells to recolonize, with in situ bonding of the mineral phase © 1998 John Wiley & Sons, Inc. J Biomed Mater Res , 39, 660–666, 1998.